NRx Pharmaceuticals, Inc.
NRXP
$2.35
$0.083.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.75% | -36.16% | 5.96% | 16.66% | 43.48% |
| Total Depreciation and Amortization | 780.00% | -40.00% | -20.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | 139.16% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9,583.02% | 1,128.84% | 1,009.46% | 346.48% | -94.47% |
| Change in Net Operating Assets | -100.45% | -106.52% | -39.40% | 2.46% | 128.58% |
| Cash from Operations | -6.53% | 14.85% | 45.70% | 50.88% | 56.20% |
| Capital Expenditure | -- | -- | -- | -- | 133.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -256,200.00% | -- | -- | -- | 133.33% |
| Total Debt Issued | 202.29% | 7,881.53% | 1,180.91% | 650.69% | -71.33% |
| Total Debt Repaid | 31.35% | -11.67% | -8.89% | -112.52% | -119.88% |
| Issuance of Common Stock | 60.18% | -38.97% | -18.59% | -27.22% | -28.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 285.70% | -- | -- | -- | -- |
| Cash from Financing | 360.35% | 1,306.31% | 262.26% | 20.71% | -74.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 176.32% | 107.74% | 127.85% | 79.61% | 22.37% |